Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
SenzaGen AB
SenzaGen Group is a leading company in in vitro science and testing, specializing in non-animal test methods to replace traditional animal testing. Their proprietary GARD® assays use genomics and…
SenzaGen AB
SenzaGen Group is a leading company in in vitro science and testing, specializing in non-animal test methods to replace traditional animal testing. Their proprietary GARD® assays use genomics and…
TL;DR
Founded: 2010 (Lund University spin-off)
Core product: GARD genomics-based, animal-free sensitization assays
Industry: Biotechnology — in vitro immunotoxicology/testing
Public status: Listed on Nasdaq First North (ticker: SENZA)
Company Overview
Problem Domain
Replacing animal-based sensitization and immunotoxicology tests with in vitro genomics-driven assays.
Founded
2010
Industry
Biotechnology
Funding Track Record
2400000
EU Horizon 2020 grant to develop GARDair (amount in EUR)
2551595
Grant funding recorded with date March 1, 2017 (amount reported in source)
Multiple RIFM grants reported (examples cited: SEK 1.5m in 2022; SEK 1.6m in 2023; SEK 3.0m in Sept 2024)